Details
New companies 3 · Follow-on 0
Stages: Undisclosed 2, Seed 1
Complaion €13.5M Funding roundMama Insurance Undisclosed New funding roundCato €6M SeedRanked by rounds participated in, from announcements in Sep 6, 2026 – Oct 5, 2026. Lead counts include only confirmed lead roles.
New companies 3 · Follow-on 0
Stages: Undisclosed 2, Seed 1
Complaion €13.5M Funding roundMama Insurance Undisclosed New funding roundCato €6M SeedNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Valon $150M Series DArmadin $255.5M Series BNew companies 1 · Follow-on 1
Stages: Series B 1, Series C+ 1
Armadin $255.5M Series BMetaview $60M Series CNew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Armadin $255.5M Series BRestate $20M Series ANew companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
Onomondo Undisclosed Majority investmentEUCLYD >€200M Series ANew companies 2 · Follow-on 0
Stages: Series C+ 1, Undisclosed 1
Tryp.com €1.9M €1.9 million funding roundTEKEVER $580M Series DNew companies 2 · Follow-on 0
Stages: Seed 1, Series B 1
Edison IA €1M SeedKaiko $57M Series B-2 extensionNew companies 2 · Follow-on 0
Stages: Seed 1, Series B 1
Humanos $3.2M SeedKaiko $57M Series B-2 extensionNew companies 2 · Follow-on 0
Stages: Seed 1, Undisclosed 1
Complaion €13.5M Funding roundCato €6M SeedNew companies 2 · Follow-on 0
Stages: Pre-seed 1, Series A 1
bilt.me $700K Pre-seedNomos €20M Series ANew companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
Complaion €13.5M Funding roundChift €10.5M Series ANew companies 2 · Follow-on 0
Stages: Pre-seed 1, Undisclosed 1
Ginmon Undisclosed Strategic investmentLimetax €36M Pre-seed equity and acquisition facilityNew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
EUCLYD >€200M Series ATandem Health $100M Series BNew companies 2 · Follow-on 0
Stages: Seed 1, Undisclosed 1
Greencovery €1M Funding roundGravity Gardens €2.6M SeedNew companies 1 · Follow-on 0
Stages: Undisclosed 1
Blue Health Intelligence €3.4M €3.4 million growth capital“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.